Construction of a 19,000m2 facility at its site in Copenhagen is the latest example of the CDMO’s growth strategy.
In February 2017, Japan’s AGC Asahi Glass (AGC) acquired CMC Biologics, a contract development and manufacturing organization (CDMO) with facilities in Seattle, Washington, and Copenhagen, Denmark.
Later that year, the firm rolled out an expansion at the Danish site adding five 2,000 L single-use bioreactors to be run in single unit operations or in unison.
Image: iStock/nantonov
In 2018, the CDMO – now rebranded together with another acquisition Biomeva as AGC Biologics – announced a further six 2,000 L single-use bioreactors would be added at the Copenhagen site. And last year, a purification line was installed as part of an $18 million global investment, considerably boosting production efficiency at the site.
Now AGC Biologics has announced a further investment in Denmark, ploughing €160 million ($192 million) to construct a facility adjacent to its current site boasting production floors with 2,000L single-use bioreactors, labs and office space.
Once operational in 2023, the facility will double the current capacity at the site, the firm has said.